AZD7503 Intervention
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Fatty Liver Disease
Conditions
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NASH
Trial Timeline
Aug 12, 2022 → Feb 27, 2024
NCT ID
NCT05560607About AZD7503 Intervention
AZD7503 Intervention is a phase 1 stage product being developed by AstraZeneca for Non-alcoholic Fatty Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05560607. Target conditions include Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05560607 | Phase 1 | Completed |
Competing Products
20 competing products in Non-alcoholic Fatty Liver Disease